[A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].

Abstract

According to estrogen receptor (ER) and menopausal status, operable breast cancer patients were randomized for adjuvant endocrine therapy with tamoxifen (TAM) in premenopausal patients, after oophorectomy (OVEX), chemotherapy, CHEM (mitomycin C+ oral cyclophosphamide), or chemo-endocrine therapy (TAM + CHEM). Some 1579 patients were entered in the trial between 9, 1978 and 12, 1991, with a median follow-up of 10 years. In ER-positive, premenopausal patients there were no significant differences in relapse-free (RFS) or overall survival (OS) among the OVEX + TAM, CHEM, and CHEM + TAM arms. On the contrary, in ER-positive, post-menopausal patients, the chemoendocrine therapy showed a significantly better OS (p = 0.0254) with a trend of better RFS (p = 0.0674), as compared with TAM or CHEM groups. ER-negative, premenopausal patients showed no significant differences in RFS or OS between CHEM and CHEM + TAM arms. In ER-negative, postmenopausal patients, there was a non-significantly better RFS (p = 0.0888) and a significantly better OS (p = 0.0332) in CHEM + TAM group than in the CHEM alone group. These results suggest that ER and menopausal status are important criteria to select early breast cancer patients for adjuvant treatments.

• Authors: Y Nomura, S Tsutsui, S Murakami, Y Takenaka
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 26 Issue 5 Pg. 643-9 (Apr 1999) ISSN: 0385-0684 [Print] Japan
• PMID: 10234295 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Antineoplastic Agents, Hormonal
• Receptors, Estrogen
• Tamoxifen
• Mitomycin
• Cyclophosphamide

Topics

• Adult
• Aged
• Antineoplastic Agents, Hormonal (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (chemistry, drug therapy, mortality, surgery)
• Chemotherapy, Adjuvant
• Cyclophosphamide (administration & dosage)
• Female
• Humans
• Mastectomy
• Menopause
• Middle Aged
• Mitomycin (administration & dosage)
• Receptors, Estrogen (analysis)
• Survival Rate
• Tamoxifen (administration & dosage)